TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04758702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L-PRF (Leucocyte- platelet rich fibrin)
Description: Leucocyte-Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly. Patient's own blood is centrifuged using (Intra-spin) FDA approved centrifuge on 45 degrees angle on 2700 rpm for 12 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H-PRF (Horizontal -platelet rich fibrin)
Description: Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly.Horizontally centrifuged platelet rich fibrin using (Bio-prf) centrifuge on 700 g force for 8 minutes. On a horizontal centrifugation, the cells separate much more efficiently throughout the entire membrane. This leads to better layer separation and also favors cells that are evenly distributed throughout the PRF clot.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical stent
Description: An essix surgical stent will be obtained using a high vacuum suction and used to protect the denuded donor site after suturing the wound. (Biostar® Scan/Biostar®V) will be used to make the stent.
Study: NCT04026880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Enanthate
Description: 25 mg testosterone enanthate administered by intramuscular injection weekly for 12 weeks
Study: NCT06385119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plixorafenib
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plixorafenib
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plixorafenib
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plixorafenib
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plixorafenib
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plixorafenib
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plixorafenib
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Oral Tablet
Study: NCT04026880

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by intramuscular injection weekly for 12 weeks
Study: NCT06201260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermittent pneumatic compression protocol
Description: A 30 min IPC protocol at about 200mmHg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: The electrodes of an electrostimulation device (SP 4.0, Compex, Guildford, United Kingdom) will be positioned on participants' quadriceps. Participants will be informed that they are engaging an innovative microcurrent treatment. This procedure will last for 30 min.
Study: NCT05189873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long GnRH agonist + HRT
Description: Intervention group:(Long GnRH agonist + HRT) From day 18-21 of the previous cycle, 0.5 cc of Superfect is injected daily and vaginal ultrasound is performed 10-14 days later If the endometrial thickness is less than 5 mm and there are no ovarian cysts, estradiol is started like HRT treatment and the agonist dose of GnRH starts with estradiol. It is halved (0.25 cc superfect) and superfect is prescribed until progesterone is started. At the time of progesterone administration, the administration of superfect is discontinued. Injections of estradiol and progesterone is the same as for the HRT group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRT
Description: In the HRT group, from the second day of the cycle, the participant receives 2 mg of estradiol daily and this drug is increased to 6 mg per day in three days.Ten days later, they undergo vaginal ultrasound to check the thickness of the endometrium. If the thickness of the endometrium is greater than 8 mm, inject able progesterone is prescribed and the patient is a candidate for FET transfer. If the thickness is less than 7 mm, it is necessary to increase the dose of estradiol and continue treatment with it. The patient undergoes vaginal ultrasound every three days and if the desired thickness does not reach 21 days after the start of the cycle, the cycle is canceled
Study: NCT05479201

Intervention type: DIAGNOSTIC_TEST
Intervention: Home based sleep test
Description: Home based sleep test to calculate apnea hypopnea index (AHI) for evaluation of sleep apnea, sleep quality (SQI) and sleep duration (SD)
Study: NCT06335602

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LASER acupuncture
Description: Low level LASER therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: LASER acupuncture
Description: Low level LASER therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASER acupuncture
Description: Low level LASER therapy
Study: NCT04246151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin capsules
Study: NCT05661786

Intervention type: OTHER
Intervention: Observation
Description: Monitor every 6 months

Intervention type: OTHER
Intervention: Antiviral treatment
Description: Receive first-line antiviral treatment, including entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir amibufenamide or peginterferon
Study: NCT05631561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular denervation System (Generator and Catheter )
Description: All patients receive endovascular denervation (EDN) treatment
Study: NCT05004831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib plus TAS-102
Description: fruquintinib 4mg/d, qd po, D1-21, Q4W; TAS-102 70mg/m2/d, bid po, D1-5, 8-12, Q4W
Study: NCT04897217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate
Description: The control arm will consist of oral progesterone therapy (megestrol acetate 160mg po daily). The intervention will be administered on an outpatient basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Drug Implant
Description: Participants in the comparison arm will have a levonorgestrel intrauterine device placed in the office or in the operating room if the office procedure not tolerated or if they have not had a prior dilation and curettage.
Study: NCT04750291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 1 infiltration in the biceps muscle with botulinum toxin (100 IU)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 infiltration in the biceps muscle with placebo or sterile saline
Study: NCT04246151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Culturelle
Description: Culturelle capsules
Study: NCT06317571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fertility support education
Description: In the first module, female reproductive organs, the occurrence of pregnancy and the effect of stress on fertility are explained to women using models and training booklets. The effects of affirmation, which is one of the ways to positively affect the consciousness, and imagination, visualization and relaxation techniques, which are ways to positively affect the subconscious, on body and reproductive functions are explained. In the second module, women and their partners were also trained, and the effect of lifestyle on reproductive health was explained through the second module training booklet. In the third module, an example of a one-week program in which they could apply the methods described in the training before starting their treatments was introduced. In the fourth module, treatment process was explained to women and the practices described in the training were shared, which they could do to relax during this process.
Study: NCT04246151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Placebo
Description: sugar pill manufactured to mimic the vancomycin 125 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vancomycin Placebo
Description: sugar pill manufactured to mimic the vancomycin 125 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic Placebo
Description: sugar pill manufactured to mimic 10 billion unit probiotic capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Placebo
Description: sugar pill manufactured to mimic 10 billion unit probiotic capsules.
Study: NCT05107895

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: online coping skills training
Description: Young people with high levels of stress were given online coping trainings. The content of this training was primarily aimed at raising awareness about stress by giving information about stress, and then information about coping methods with stress was shared and training on problem solving skills was provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online coping skills training
Description: Young people with high levels of stress were given online coping trainings. The content of this training was primarily aimed at raising awareness about stress by giving information about stress, and then information about coping methods with stress was shared and training on problem solving skills was provided.
Study: NCT04535635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Release Techniques®
Description: The ART® procedure will consist of identifying and treating manipulatable lesions as per their protocols, while the sham group will receive a passable version of this technique. This information is under copyright and cannot be copied or outlined specifically in any form, including a research paper. The overarching procedure used by ART® will be explained however specific details referring to each protocol cannot be described. Muscles are shortened, and the therapist applies sufficient digital pressure to be in contact with the tissue in question. Directional tension is applied proximally along the muscle fiber direction, and then the structure is lengthened while the contact remains as described.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Active Release Techniques®
Description: For the sham treatment, the muscle(s) in question will be taken from a lengthened to a shortened position (opposite of the protocol direction as per the ART® manual) with a broad light contact on the skin - the treating therapist will not achieve tissue depth as specified by ART® and will not attempt to take tension as is outlined in the ART® manual.
Study: NCT05296265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR treatment for phantom limb pain
Description: 8 twice-weekly interventions of 1 hour; baseline, pre-intervention; immediately after the end of the in intervention; 1 week after the end of the intervention; 8 weeks after the end of the intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR treatment for phantom limb pain
Description: 8 twice-weekly interventions of 1 hour; baseline, pre-intervention; immediately after the end of the in intervention; 1 week after the end of the intervention; 8 weeks after the end of the intervention
Study: NCT05087771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injectable naltrexone
Description: 360 mg dose to be given prior to hospital discharge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral naltrexone
Description: 50 mg tab dispense 30 day supply to be given at hospital discharge
Study: NCT05579977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Oral glucagon-like peptide-1 receptor agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Oral glucagon-like peptide-1 receptor agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Oral glucagon-like peptide-1 receptor agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Oral glucagon-like peptide-1 receptor agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Oral glucagon-like peptide-1 receptor agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Oral glucagon-like peptide-1 receptor agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Oral glucagon-like peptide-1 receptor agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Oral glucagon-like peptide-1 receptor agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Oral glucagon-like peptide-1 receptor agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Oral glucagon-like peptide-1 receptor agonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rybelsus
Description: Oral Semaglutide
Study: NCT05979948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib, 160 mg oral capsules twice daily for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine, 70-90 mg/m2 on days 1 and 2 of each cycle for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab, 375 mg/m2 intravenously on day 0 of each cycle for 6 cycles
Study: NCT05574023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Predictive Alarm for hypoglycaemia or hyperglycaemia
Description: Patients use CGM sensor with Predictive Alarm set at 70 mg/dl in 20 minutes for hypoglycemia and at 250 mg/dl in 20 minutes for hyperglycemia.~1. in case of alarm from the hypoglycemia predictive algorithm, the indicated treatment was 0.1g of sugar/kg of body weight;~2. in case of alarm from the hyperglycemia predictive algorithm, the indication was to give an extra shot of rapid-acting insulin. The dose will be calculated on the basis of personal insulin sensitivity factor (ISF), considering as target a blood glucose of 120 mg/dl and 250 mg/dl as the projected blood glucose level that will be reached in 20 minutes. This could be done only if there is no active insulin on-board, after at least 3 hours from the last rapid-acting insulin injection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of Alarm on Threshold for hypoglycaemia or hyperglycaemia
Description: in case of alarm of hypoglycemia, the indicated treatment was 0.3g of sugar/kg of body weight, max 15g.~in case of alarm of hyperglycemia, the indication will be to give an extra shot of rapid-acting insulin. The dose will be calculated on the basis of personal insulin sensitivity factor (ISF), considering as target a blood glucose of 120 mg/dl and 250 mg/dl as blood glucose level to correct. This could be done only if there is no active insulin on-board, after at least 3 hours from the last rapid-acting insulin injection.
Study: NCT05706922

Intervention type: OTHER
Intervention: Venous blood sample, vaginal swab
Description: Venous blood samples and vaginal swab will be obtained on the same day.

Intervention type: OTHER
Intervention: Venous blood sample, vaginal swab
Description: Venous blood samples and vaginal swab will be obtained on the same day.
Study: NCT03941496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: In Phase Ib dose escalation stage, 24 participants will receive AZA subcutaenously once a day for 5 days as follows:~1. 5 mg/m\^2~2. 15 mg/m\^2~3. 30 mg/m\^2~4. 50 mg/m\^2~5. 75 mg/m\^2~Results from Phase Ib are sent to FDA/IRB for approval before proceeding to Phase IIa. 36 subjects will receive AZA treatment in total (Phase Ib/IIa). Subjects in Phase II will receive a dose that induces two of the three following:~1. a decrease DNA methylation levels in genes previously identified to be persistently hyper-methylated despite successful anti-TB therapy~2. an increase in TNF and IFN-γ signaling pathways~3. an increase in ex vivo mycobacterial growth inhibition assay
Study: NCT06202222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: The patient undergoes a daily session on the cycloergometer (Am3i Ergometer). The patient is instructed to pedal at a heart rate ranging from 60% to 80% of their maximum heart rate (calculated as 220 minus their age) for a duration of 20 minutes. These sessions can be conducted with oxygen therapy for patients dependent on oxygen. The sessions are maintained until the patient is discharged from the department.
Study: NCT05272618

Intervention type: DIAGNOSTIC_TEST
Intervention: Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)
Description: Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)

Intervention type: DIAGNOSTIC_TEST
Intervention: Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)
Description: Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)
Study: NCT04452565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: NA-831
Description: NA-831 is a neuroprotective drug, available at 30 mg capsule

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: NA-831 and Atazanavir
Description: Drug: NA-831 Neuroprotective drug Other Name: Traneurocin 30 mg capsule~Drug: Atazanavir Sulfate Antiviral drug Other Name: Atazanavir Sulfate 200 mg tablet

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: NA-831and Dexamethasone
Description: Drug: NA-831 Neuroprotective drug Other Name: Traneurocin 30 mg capsule~Drug: Dexamethasone anti-inflammatory drug Other Name: Dexamethasone 4 mg

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir and Dexamethasone
Description: Drug: Atazanavir Sulfate Antiviral drug Other Name: Atazanavir Sulfate 200 mg tablet Drug: Dexamethasone anti-inflammatory drug Other Name: Dexamethasone 4 mg
Study: NCT04021550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure CPAP
Description: All subjects will be advised to use their continuous positive airway pressure (CPAP) in accordance to their physician's guidelines.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Positive Airway Pressure CPAP
Description: All subjects will be advised to use their continuous positive airway pressure (CPAP) in accordance to their physician's guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg
Description: Subjects in this group will receive 80mg/day of Telmisartan (an angiotensin receptor blocker). Treatments will be administered in pre-packaged blister packages. Subjects will take Telmisartan once per day for 6 weeks.
Study: NCT06189326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-penetrating deep sclerectomy
Description: Non-penetrating deep sclerectomy (NPDS) is a non-perforating filtration procedure used for the surgical treatment of medically uncontrolled open angle glaucoma. This procedure was developed in an attempt to avoid many of the postoperative complications of trabeculectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary combined trabeculotomy-trabeculectomy
Description: Combining trabeculotomy with trabeculectomy is one of the preferred surgical options, which showed favorable results in congenital glaucoma, and is advised mainly for treating moderate to severe forms of the disease, as the procedure provides dual pathways for aqueous drainage
Study: NCT04021550

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-Lipoic Acid 600mg
Description: Subjects in this group will receive 600mg/day of Alpha-Lipoic Acid (an antioxidant). Treatments will be administered in pre-packaged blister packages. Subjects will take Alpha-Lipoic Acid once per day for 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose
Description: Subjects in this group will receive two capsules of Microcrystalline Cellulose (placebo). Treatments will be administered in pre-packaged blister packages. Subjects will take placebo pills once per day for 6 weeks.